• LabCorp completes acquisition of Chiltern for $1.2bn pharmaceufical-technology
    September 05, 2017
    US-based global life sciences company LabCorp has completed the acquisition of Chiltern, a specialist contract research organisation (CRO), for approximately $1.2bn.
PharmaSources Customer Service